Skip to main content
. Author manuscript; available in PMC: 2011 Aug 15.
Published in final edited form as: Liver Transpl. 2007 Jan;13(1):122–129. doi: 10.1002/lt.20995

Figure 3.

Figure 3

A total of 123 patients had at least 1 biopsy that occurred ≥30 days posttransplantation and no more than 2 weeks after the start of HCV treatment and had an Ishak fibrosis score. The cumulative risk of Ishak fibrosis score of 3 or more (bridging fibrosis or cirrhosis) on biopsy was not significantly different among LDLT ≤20 (solid line; n = 28), LDLT >20 (dashed line; n = 43), and DDLT (dotted line; n = 52) groups (P > 0.05 for all comparisons by log-rank test, unadjusted). Patients were censored at time of treatment of HCV disease.